Advanced Oncotherapy – Additional Director Dealing

Advanced Oncotherapy (AVO) announces that Michael Sinclair, Executive Chairman of the Company, on 18 December 2015 purchased 500,000 ordinary shares of 1 penny each in the Company at 6.25 pence per Ordinary Share. The Company also announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, […]

Advanced Oncotherapy – Additional Director Dealing

Advanced Oncotherapy (AVO) announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 1,000,000 ordinary shares of 1 penny each in the Company at 5.75 pence per Ordinary Share. Following this transaction, Michael Bradfield now holds 123,768,510 Ordinary Shares representing 8.73% of the issued […]

Advanced Oncotherapy – Director Dealing

Advanced Oncotherapy (AVO) announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 750,000 ordinary shares of 1 penny each in the Company at 5.5 pence per Ordinary Share. Following this transaction, Michael Bradfield now holds 122,768,510 Ordinary Shares representing 8.66% of the […]

Advanced Oncotherapy – Scientists put final pieces in place for seeing cancer with protons

Scientists are currently putting together a unique medical imaging platform that could improve treatment for millions of cancer sufferers by making proton therapy a viable option. Members of the multi-national research team behind the Proton Radiotherapy Verification and Dosimetry  Applications (PRaVDA) project, led by the University of Lincoln, UK, are now building the instrument that will produce […]

Bid for cutting-edge cancer treatment centre submitted

Bid for cutting-edge cancer treatment centre submitted. A planning application has now been submitted for a state-of-the-art cancer centre in Northumberland – likely to be the first to become operational in England. An example of how the treatment rooms will look at the new centre. As reported earlier this year, the Proton Beam Therapy treatment centre, […]

Advanced Oncotherapy announces the appointment of an Executive Chairman at subsidiary ADAM

Advanced Oncotherapy announces that Professor Steve Myers OBE, Head of Medical Applications at CERN, has been appointed as Executive Chairman of Advanced Oncotherapy’s fully owned subsidiary ADAM S.A.  ADAM was founded in 2007 as a spin-off from CERN, the European Organisation for Nuclear Research, and was acquired by Advanced Oncotherapy in 2013. The ADAM team […]

Advanced Oncotherapy announces the disposal of Oncotherapy Resources Ltd

Advanced Oncotherapy announces that it has disposed of its subsidiary, Oncotherapy Resources Ltd (“ORL”), for a total cash consideration of £100,000. An initial cash payment of £75,000 has been received with the remainder to be paid on the first anniversary of the disposal. ORL focuses on supplying a fully mobile managed service delivering electronic brachytherapy […]